As other high-income nations and ongoing clinical trials integrate neoadjuvant pertuzumab as a standard of care for curative-intent treatment of HER2-positive breast cancer, the majority of Canadian patients outside of Quebec will continue to be at a significant disadvantage due to the negative reimbursement decision by CADTH, which closes the door to access. Here, ERBB2 is linked to breast carcinoma.